We are a financial services provider for several types of professional clients, each with distinct needs.
BUSINESS ACCOUNT
Access reports individually or via Subscription
Receive monthly invoices with payment via CSA or hard dollars
Analyst access
Free Trial Subscriptions
Team account with shared subscriptions
Advanced analytics to track research consumption and performance
We provide more colour in this note on our change in TP and recommendation following ASMi FY25 results, which were good given the improved outlook. We see upside on the FY26 estimates, yet expectations for FY27 are already high and leave little room for upside, while the valuation is also above the historical average. We derive a fair value of €658 p.s. based on our FY27 diluted EPS of € 22.1 and a PE multiple of 30x. Given the downside we reduced our recommendation this morning from Accumulate ...
According to Bloomberg, D'Ieteren Group has appointed Rotschild to explore strategic options for its controlling stake in Belron, people familiar with the matter said. Options considered include an IPO in the US or in the EU, with a valuation of upwards of $30bn and close to $40bn. Deliberations are preliminary and D'Ieteren could decide to keep its stake in Belron, people said. Any IPO plan would need to be agreed by the entire ownership of Belron, including CD&R, H&F, GIC and Blackrock. In thi...
UCB and Antengene entered into an exclusive worldwide license agreement to further develop, manufacture and commercialize ATG-201, a preclinical CD19/CD3 bispecific T-cell engager. UCB will pay $ 80m in upfront and near-term milestone payments, development and commercial milestones of up to approx. $ 1.1bn, and royalties on future sales. ATG-201, being a bispecific T-cell engager, builds on UCB's autoimmune expertise, and given its potential to address a broad set of B-cell driven autoimmune dis...
Care Property Invest reports FY25 in line with its 3Q25 guidance. In line with previous quarters there was a negative leasing spread (-1.08%), but the EPRA cost ratio further improved to 15.6% (+110bps). The FY26 outlook of € 1.07 EPRA EPS is below our expectations (€ 1.09) and below the € 1.11 consensus estimates. The difference is driven by the Apricusa bankruptcy announced early January (- € 0.02 EPRA EPS impact), lower than expected indexation forecasts (i.e. 1.3% for BE) and rent cuts/provi...
Rising interest rates are becoming a hot topic, triggered by a significant uptick in US 10-year treasury yields through February and March. In this note we revisit this topic from several angles. We dig into the empirical side of what we can reasonably expect from the market as a whole when interest rates start to rise. Secondly we review our coverage, putting forward a number of impacted sectors and stocks.